Hims & Hers Health: Strategic Expansion Into at-Home Laboratory Tests – Canaccord Raises Price Target from $38 to $68!
Reading Time: 3 minutes
Market Expansion Home Tests: Acquisition of Trybe Labs opens up high-margin health segments and strengthens personalized treatment offerings. Price target increases by nearly 80 %: Analysts show optimism – Canaccord raises price target to $68. Hims & Hers Health (NYSE: HIMS) continues its ambitious growth strategy: With the acquisition of Sigmund NJ LLC (Trybe Labs), the company taps into the rapidly growing market for at-home laboratory tests. This expansion aims to significantly enhance the range of personalized treatments and...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
